Your browser doesn't support javascript.
loading
Serum concentrations of estriol vary widely after application of vaginal oestriol cream.
Te West, Nèvine; Day, Richard; Graham, Garry; Wright, Michael; White, Christopher; Popovic, Gordana; Moore, Kate Hilda.
Afiliación
  • Te West N; Department of Urogynaecology, St George Hospital, School of Women's and Children's Health, University of NSW, Sydney, Australia.
  • Day R; Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Sydney, Australia.
  • Graham G; St Vincent's Clinical School, Faculty of Medicine, University of NSW, Sydney, Australia.
  • Wright M; Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Sydney, Australia.
  • White C; NSW Health Pathology Clinical Chemistry and Endocrinology, Prince of Wales Hospital, Sydney, Australia.
  • Popovic G; Drug Development Solutions, LGC, Fordham, UK.
  • Moore KH; NSW Health Pathology Clinical Chemistry and Endocrinology, Prince of Wales Hospital, Sydney, Australia.
Br J Clin Pharmacol ; 87(5): 2354-2360, 2021 05.
Article en En | MEDLINE | ID: mdl-33129232
ABSTRACT

AIMS:

The aim of this study was to establish the pharmacokinetic profile of serum oestriol (E3 ) concentrations over 24 h following application of vaginal E3 in chronic users (>12 weeks of E3 use). The interindividual and intraindividual differences before and after E3 were examined.

METHODS:

Ten women participated. Vaginal cream was omitted for ≥36 h prior to the study days. Blood sampling was performed for E3 , oestradiol and oestrone concentrations prior to cream application and at 1, 2, 3, 5, 8, 10, 12 and 24 h afterwards. In five women, all samples were repeated on a separate day.

RESULTS:

E3 was absorbed rapidly in most women. Peak serum E3 concentration occurred around 2 h (range 1-5 h). The decline in E3 concentrations was also rapid falling <100 pmol L-1 in six out of ten women within 8 h and returning to ≤ 10 pmol L-1 at 24 h in nine out of the ten patients. Interindividual variability for peak concentrations was considerable (mean 546 pmol L-1 ; 95% CI 349-743). Area under the concentration-time curve (AUC) values over a dosage interval also varied widely mean 2145 pmol.h L-1 ; 95% CI 1422-3233. However, repeated measurements in the same woman were highly (peaks ρ = 0.94) or moderately (AUC P = 0.74) correlated.

CONCLUSIONS:

Postmenopausal E3 concentrations are negligible. Serum E3 concentrations of chronic users of E3 cream varied greatly; however, concentrations declined rapidly within 8 h, generally reaching 'postmenopausal' levels by 24 h. The basis for the variation between subjects needs further elucidation. Additional research is required to establish the safety of topical E3 .
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cremas, Espumas y Geles Vaginales / Estriol Límite: Female / Humans Idioma: En Revista: Br J Clin Pharmacol Año: 2021 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cremas, Espumas y Geles Vaginales / Estriol Límite: Female / Humans Idioma: En Revista: Br J Clin Pharmacol Año: 2021 Tipo del documento: Article País de afiliación: Australia